Pendulum Therapeutics fetches $54m Series C

Pendulum Therapeutics, a biotech company targeting the microbiome, has secured $54 million in Series C funding.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this